Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205135 | 0.84 | CCR3 (0.52) | HTR1ASLC6A4CCR3MAPK1KDM4E | |
| SCHEMBL5205031 | 0.81 | HTR1A (0.81) | HTR1ASLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5208198 | 0.80 | HTR1A (0.80) | HTR1ASLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5208193 | 0.77 | HTR1A (0.55) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6409944 | 0.75 | HTR1A (0.56) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6411160 | 0.74 | HTR1A (0.54) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL5204948 | 0.71 | HTR1A (0.62) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL5205147 | 0.71 | HTR1A (1.00) | HTR1ASLC6A4 | |
| SCHEMBL5208014 | 0.71 | HTR1A (0.80) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL5206610 | 0.70 | HTR1A (0.91) | HTR1ASLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | HTR1A 3/4885SLC6A4 10/4885CYP2D6 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.